Table 1.
Treatment-emergent adverse events occurring in ≥5% of patients or with between-groups p <.10
| OLZ LAI 150 (N = 140) | OLZ LAI 405 (N = 318) | OLZ LAI 300 (N = 141) | Overall p-valuea | Cochran-Armitage Test p-value | |
|---|---|---|---|---|---|
| Anxiety | 5 (3.57%) | 17 (5.35%) | 7 (4.96%) | .767 | .686 |
| Headache | 7 (5.00%) | 9 (2.83%) | 3 (2.13%) | .355 | .216 |
| Increased appetite | 1 (0.71%) | 3 (0.94%) | 5 (3.55%) | .080 | .031 |
| Insomnia | 11 (7.86%) | 23 (7.23%) | 9 (6.38%) | .871 | .632 |
| Nasopharyngitis | 8 (5.71%) | 11 (3.46%) | 7 (4.96%) | .442 | .947 |
| Schizophrenia | 6 (4.29%) | 3 (0.94%) | 2 (1.42%) | .047 | .165 |
| Somnolence | 8 (5.71%) | 10 (3.14%) | 5 (3.55%) | .367 | .467 |
| Weight increased | 12 (8.57%) | 16 (5.03%) | 15 (10.64%) | .071 | .267 |
Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
aTest of overall group differences based on Fisher's exact test.